$0.00
−84.62%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 11Sep 16Sep 21Sep 24
Key dataSep 24, 2026
Open$0.08
From 52W high−99.86%
Volume863065.00
Market cap$3316.00
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 24, 2026
Open
$0.08
From 52W high
−99.86%
Volume
863065.00
Market cap
$3316.00
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
19.5
MomentumView details →
1D Return
−84.62%
YTD Return
−99.50%
SummaryUpdated Jun 1, 2026
Jasper Therapeutics, Inc. (NASDAQ:JSPR) is a clinical-stage biotechnology company founded in 2020 and based in Redwood City, California. The company specializes in developing innovative therapeutic agents for hematopoietic stem cell transplantation and gene therapies, with a focus on conditioning agents and stem cell engineering technologies. Since going public in January 2020, Jasper has been advancing its pipeline of experimental treatments designed to expand the use of stem cell transplantation and improve outcomes for patients requiring these life-saving procedures.
Similar companies
Latest newsMore news →
Jasper Therapeutics completed enrollment in the IgA nephropathy cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104).5d agoJasper Therapeutics commenced an offer to purchase all outstanding warrants issued in its September 18, 2025 public offering for $0.324 in cash per warrant; tendered warrants will be retired and cancelled.13d ago